The U.S. Food and Drug Administration (FDA) announced on December 4, 2025, the approval of a new indication for Breyanzi (lisocabtagene maraleucel), making it the first chimeric antigen receptor (CAR) T-cell therapy authorized in the country to treat adults with marginal zone lymphoma (MZL) who have not responded to or have relapsed after at least two prior lines of treatment.

Breyanzi is a personalized immunotherapy in which T cells are taken from the patient, genetically modified to recognize a target on tumor cells, and then reinfused to destroy the cancer.

The FDA emphasizes that this approval is a significant advance in precision medicine because it transforms the patient's own immune system into a more effective therapeutic tool against this type of lymphoma.

WHOM DOES IT IMPACT?

The direct impact is felt by adult patients, hematologists, oncologists, specialized centers, and healthcare systems.

CONCLUSION:

This approval represents a significant leap forward for a small but high-need group, opening the CAR-T pathway for MZL for the first time and offering an alternative for profound and sustained responses where previously there were limited options.